Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will ...
Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results